Drug behemoth Pfizer is allegedly considering the sale of the pumps and devices business that the company acquired during its purchase of Hospira last year in a deal that could fetch as much as $2 billion for the U.S. drugmaker, according to Bloomberg Business.
The possible sale, however, is allegedly still in its initial stages, and its details and specifics are still subject to change, sources who have chosen to remain anonymous have said. As of writing, the drug giant might even choose to not sell the pumps and devices business.
Pfizer has refused to provide any information about the alleged sale, with a spokeswoman from the drug company declining to comment on the matter, reported Reuters.
Hospira, a company that makes biosimilars and generic versions of injectable drugs, was purchased by Pfizer in September 2015 in a deal that amounted to about $17 billion. The acquisition bolstered the U.S. drugmaker's portfolio of established drugs, including off-patent medicines.
Investors have reacted quite positively to the possibility of the sale, pushing Pfizer's shares 0.1 percent, ending in $30.42 in pre-market trading on Thursday, according to The Street.
Pfizer has made a lot of waves last year when it announced that it has agreed to a merger with another drug company, Allergan Plc, in a deal that would be worth about $160 billion. If approved by antitrust authorities, it would form the largest ever drug behemoth in the pharmaceutical industry.
Check out more Business News here.
